Contribution of local regeneration of glucocorticoids to tissue steroid pools

11β-Hydroxysteroid dehydrogenase 1 (11βHSD1) is a drug target to attenuate adverse effects of chronic glucocorticoid excess. It catalyses intracellular regeneration of active glucocorticoids in tissues including brain, liver and adipose tissue (coupled to hexose-6-phosphate dehydrogenase, H6PDH). 11βHSD1 activity in individual tissues is thought to contribute significantly to glucocorticoid levels at those sites, but its local contribution vs glucocorticoid delivery via the circulation is unknown. Here, we hypothesised that hepatic 11βHSD1 would contribute significantly to the circulating pool. This was studied in mice with Cre-mediated disruption of Hsd11b1 in liver (Alac-Cre) vs adipose tissue (aP2-Cre) or whole-body disruption of H6pdh. Regeneration of [9,12,12-2H3]-cortisol (d3F) from [9,12,12-2H3]-cortisone (d3E), measuring 11βHSD1 reductase activity was assessed at steady state following infusion of [9,11,12,12-2H4]-cortisol (d4F) in male mice. Concentrations of steroids in plasma and amounts in liver, adipose tissue and brain were measured using mass spectrometry interfaced with matrix-assisted laser desorption ionisation or liquid chromatography. Amounts of d3F were higher in liver, compared with brain and adipose tissue. Rates of appearance of d3F were ~6-fold slower in H6pdh-/- mice, showing the importance for whole-body 11βHSD1 reductase activity. Disruption of liver 11βHSD1 reduced the amounts of d3F in liver (by ~36%), without changes elsewhere. In contrast disruption of 11βHSD1 in adipose tissue reduced rates of appearance of circulating d3F (by ~67%) and also reduced regenerated of d3F in liver and brain (both by ~30%). Thus, the contribution of hepatic 11βHSD1 to circulating glucocorticoid levels and amounts in other tissues is less than that of adipose tissue.

Effectiveness and safety of bipolar ablation of heart arrhythmia. A systematic review with meta-analysis

Funding Acknowledgements

Type of funding sources: Public grant(s) – National budget only. Main funding source(s): The National Centre for Research and Development, Poland

Introduction

Bipolar radiofrequency ablation (BFRA) emerged as a viable technique of radiofrequency ablation where the standard unipolar approach (RFA) failed. A number of studies describing BRFA were published recently suggesting high effectiveness and acceptable safety of this technology for ablation of ventricular tachycardia in structural heart disease (SHD VT), premature ventricular contractions (PVC) or atrial flutter (AFL).

Purpose

We performed a systematic review with meta-analysis of available evidence to assess contemporary evidence on the effectiveness and safety of bipolar ablation of heart arrhythmia.

Methods

We systematically searched MEDLINE, EMBASE, and CENTRAL databases from inception to 27 August 2022 for prospective and retrospective studies with or without a control group. We also contacted BRFA experts to obtain information on the most up-to-date studies or conference presentations. Case studies and papers describing technical aspects of BRFA rather than clinical outcomes were excluded. Study quality was assessed using the Newcastle–Ottawa Scale.

Results

Out of 1919 records we included 12 studies: one good quality case-control study and 11 low-quality case series without a control group. Studies described 120 patients who received BFRA: mean age 61.9±10.3 years, 81% males, mean ejection fraction 43.2±12.4, SHD 62.6%, ICD/CRT-D 52.2%. Almost all patients were qualified to BRFA due to failure of at least one unipolar RFA. Follow-up period differed between studies and ranged between 1-2 years in most cases.

The overall acute effectiveness of BRFA was 88.2% (95%CI 82.5-93.8), I2=6.7%. The overall effectiveness of a first BRFA at the end of the follow-up period was 55% (95%CI 46.2-63.7), I2=7.2%. There was a need for a re-ablation in 21.2% patients (95%CI 11.2-31.2), I2=64%. A subgroup analysis for SHD VT, PVC and AFL yielded similar results. There were 16 serious complications including one surgical intervention and no acute deaths; five patients died during the follow-up, mainly due to heart failure progression.

Conclusions

Bipolar radiofrequency ablation may be an effective and safe procedure in selected patients who failed at least one unipolar radiofrequency ablation but the quality of the supporting evidence is generally low.

AB0198 EFFICACY AND SAFETY AFTER TRANSITION FROM REFERENCE ADALIMUMAB TO CT-P17 (ADALIMUMAB BIOSIMILAR: 100 MG/ML) IN COMPARISON WITH THE MAINTAINED TREATMENT (CT-P17 OR REFERENCE ADALIMUMAB) IN PATIENTS WITH MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS: 1-YEAR RESULT

Background:

Therapeutic equivalence of CT-P17 to reference adalimumab (ref-adalimumab) has been shown in patients with moderate-to-severe active rheumatoid arthritis (RA) through primary 24-week results [1]. Here, efficacy, pharmacokinetics (PK), safety and immunogenicity results up to 52-week, including transition data from ref-adalimumab to CT-P17 are presented.

Objectives:

To evaluate efficacy, PK, safety and immunogenicity when switched from ref-adalimumab to CT-P17 compared to maintaining CT-P17 or ref-adalimumab.

Methods:

In this study, 648 moderate-to-severe active RA patients despite methotrexate treatment were randomized (1:1) to either CT-P17 or ref-adalimumab and treated with doses of 40 mg every 2 weeks up to Week 24. Prior to dosing at Week 26, 608 patients were randomized again to either maintaining their treatments or being switched from ref-adalimumab to CT-P17. Efficacy, PK, safety, and immunogenicity were assessed up to Week 52.

Results:

After the second randomization, 303 patients continued with CT-P17, 153 patients continued with ref-adalimumab and 151 patients switched from ref-adalimumab to CT-P17 treatments, up to Week 48. Demographics and baseline characteristics were similar among the 3 groups. Sustained and comparable efficacy in terms of ACR20/50/70 response rates was achieved not only in the maintenance groups (CT-P17 or ref-adalimumab) but also in the switched from ref-adalimumab to CT-P17 group up to Week 52 (Figure 1).

Figure 1.

ACR 20/50/70 Response Rates up to 1 YearAbbreviation: ref-adalimumab, reference adalimumab.Note. There were patients who could not visit the study site due to COVID-19 pandemic and were counted as nonresponder for ACR response at Week 52.

In terms of PK, mean trough serum concentration (Ctrough) were maintained after Week 24 in all 3 groups. The observed mean Ctrough were within the reported therapeutic ranges of ref-adalimumab trough levels in RA patients (5-8 μg/mL).

The safety profile after transition was comparable among the 3 groups (Table 1). The most common treatment-emergent adverse events (TEAEs) was neutropenia. Similar proportions of patients in all 3 groups experienced at least 1 TEAE: injection site reactions, hypersensitivity/allergic reactions and infections. One malignancy (basal cell carcinoma; unrelated) was reported in the ref-adalimumab maintenance group. Safety data accumulated over 1 year also showed comparable results among the 3 groups. Anti-drug antibody (ADA) and neutralizing antibody (NAb) results were similar among the 3 groups. At Week 52, the proportions of patients who had ADA/NAbs were 28.4%/24.8% patients in CT-P17 maintenance, 27.0%/24.3% patients in ref-adalimumab maintenance and 28.3%/26.3% patients in switched to CT-P17 groups.

Conclusion:

Single transition from ref-adalimumab to CT-P17 was efficacious and safe without increase in immunogenicity. Also, efficacy, PK, safety and immunogenicity profiles were comparable between CT-P17 and ref-adalimumab up to Week 52.

References:

[1]J Kay et al, 2020. Poster Presented at ACR Convergence 2020.

Table 1.

Overview of TEAEs from Weeks 26 to 52 (Safety Population – second random subset)

Patients, n (%)Second RandomizationCT-P17 Maintenance(N=303)Ref-ada Maintenance(N=152)Switched to CT-P17 (N=152)≥1 TEAE121 (39.9)69 (45.4)73 (48.0)≥1 TESAE6 (2.0)3 (2.0)5 (3.3)≥1 TEAE leading to study drug discontinuation3 (1.0)2 (1.3)5 (3.3)≥1 TEAE classified as hypersensitivity/allergic reactions2 (0.7)1 (0.7)0 (0)≥1 TEAE classified as injection site reactions1 (0.3)4 (2.6)1 (0.7)≥1 TEAE classified as infection54 (17.8)41 (27.0)28 (18.4)≥1 TEAE classified as malignancy0 (0)1 (0.7)0 (0)

Abbreviations: Ref-ada, reference adalimumab; TEAE, treatment-emergent adverse event; TESAE, treatment-emergent serious adverse event.

Disclosure of Interests:

Daniel Furst Speakers bureau: CME, Consultant of: Amgen, Corbus, Galapagos, Horizon, Kadmon, Pfizer, Talaris, Grant/research support from: Corbus, CSL Behring, Galapagos, Gilead, GSK, Horizon, Kadmon, Novartis, Pfizer, Roche/Genetech, Talaris, Edward Keystone Speakers bureau: Amgen, AbbVie, F. Hoffmann-La Roche Inc., Janssen Inc., Merck, Novartis, Pfizer Pharmaceuticals, Sanofi Genzyme, Consultant of: AbbVie, Amgen, Bristol-Myers Squibb Company, Celltrion Inc., Myriad Autoimmune, F. Hoffmann-La Roche Inc, Gilead, Janssen Inc., Lilly Pharmaceuticals, Merck, Pfizer Pharmaceuticals, Sandoz, Sanofi-Genzyme, Samsung Bioepis, Grant/research support from: Amgen, Merck, Pfizer Pharmaceuticals, PuraPharm, Jonathan Kay Consultant of: AbbVie, Inc., Boehringer Ingelheim GmbH, Celltrion Healthcare Co. Ltd., Jubilant Radiopharma, Merck & Co., Inc., Pfizer Inc., Samsung Bioepis, Sandoz Inc., Scipher Medicine, UCB, Inc., Grant/research support from: Paid to the University of Massachusetts Medical School: Gilead Sciences Inc., Novartis Pharmaceuticals Corp., Pfizer Inc., Janusz Jaworski: None declared, Rafal Wojciechowski: None declared, Piotr Wiland Speakers bureau: Eli Lilly, Sanofi Aventis, Novartis, Sandoz, Consultant of: Eli Lilly, Novartis, Sandoz, Anna Dudek: None declared, Marek Krogulec: None declared, Sławomir Jeka Speakers bureau: Novartis, Pfizer, Roche, Lilly, Teva, MSD, Abbvie, Sandoz, Egis, Medac, Consultant of: Novartis, Pfizer, Roche, Lilly, Teva, MSD, Abbvie, Sandoz, Egis, Medac, Agnieszka Zielinska: None declared, Jakub Trefler: None declared, Katarzyna Bartnicka-Masłowska: None declared, Magdalena Krajewska-Wlodarczyk Speakers bureau: Abbvie, Eli Lilly, Novartis, Roche, Piotr Klimiuk: None declared, Sang Joon Lee Employee of: Celltrion, Inc., Sung Hyun Kim Employee of: Celltrion, Inc., YunJu Bae Employee of: Celltrion, Inc., GoEun Yang Employee of: Celltrion, Inc., JaeKyoung Yoo Employee of: Celltrion, Inc., TaeKyung Kim Employee of: Celltrion, Inc.

Innovation Activity Development of Urban Public Transport Service Providers: Multifactor Economic and Mathematical Model

Systematization literary sources and approaches for solving the problem of ecologists of «smart» city indicates that among factors that probably can affect the innovativeness of Ukrainian providers of urban public transport services have been used environmental factor, marketing expenses, financial potential, wear rate, level of quality of service, level of management skills, market share, tariff for passenger transportation. The purpose of the study is to identify the ways to improve the innovativeness of urban public transport service providers of the regional centres of Ukraine. The main aim of the research is to estimate the impact of several factor variables on the resulting attribute used multivariate regression analysis, which provided an adequate model. A significant contribution to the development of the theory and methodology of management of urban public transport enterprises were made by Nunes, Krasnyanskiy, Umpleby, Walters, Huang, Morchadze. The results of the evaluation of the innovativeness of Ukrainian providers of urban public transport services carried out based on the mathematical multifactor model are presented in the article. In January-March 2018, the authors initiated a study on the current state of urban public transport in regional Ukrainian cities. Methodological tools of the research were multivariate correlation-regression analysis and survey (the requests for public information were submitted by the Law of Ukraine «On Access to Public Information» to all city councils of Ukraine's regions except temporarily occupied territories). The study included a survey of 20 experts (marketers and experienced managers of transport companies) to determine weighting factors and the level of innovativeness through questionnaires. The expert evaluation was carried out using the marks method. The research has shown that the size of the innovativeness of providers of public transport services can be successfully interpreted through functional and statistical dependencies, which reflect the general and individual laws of the development of such entities using multi-factor mathematical models. The econometric model was tested for the adequacy with the Fisher criterion and the presence of autocorrelation. The research empirically confirms and theoretically proves thatsuch controllable factors are an environmental factor, financial potential, level of quality of service, level of management skills, the tariff for passenger transportation. The model can be used to predict the influence of controllable factors at the level of the innovativeness of providers of urban public transport services. The results of the research can be useful for scientific and practical workers, teachers, students of higher educational establishments. Keywords: econometric model, factors of innovativeness, innovativeness, urban transport, ecologists.

Melatonin-induced glycosaminoglycans augmentation in myocardium remote to infarction

Elevated levels of collagen as well as transient increases of glycosaminoglycans (GAG) have been shown in the myocardium remote to the infarction. The aim of the study is to observe the effect of melatonin on the accumulation of collagen and GAG in the left ventricle wall, remote to the infarction. A second aim is to determine whether the effect of the pineal indole is mediated by the membrane melatonin receptors of heart fibroblasts. Rats with myocardial infarction induced by ligation of the left coronary artery were treated with melatonin at a dose of 60 μg/100 g b.w. or vehicle (2% ethanol in 0.9% NaCl). The results were compared with an untreated control. In the second part of the study, the fibroblasts from the non-infarcted part of myocardium were isolated and cultured. Melatonin at a range of concentrations from 10(-8) M to 10(-6) M was applied to the fibroblast cultures. In the final part of the study, the influence of luzindole (10(-6) M), the melatonin membrane receptor inhibitor, on melatonin-induced GAG augmentation was investigated. Both collagen and GAG content were measured in the experiment. Melatonin elevated GAG content in the myocardium remote to the infarcted heart. Collagen level was not changed by pineal indoleamine. Fibroblasts isolated from the myocardium varied in shape from fusiform to spindle-shaped. Moreover, the pineal hormone (10(-7)M and 10(-6)M) increased GAG accumulation in the fibroblast culture. Luzindole inhibited melatonin-induced elevation of GAG content at 10(-6)M. Melatonin increased GAG content in the myocardium remote to infarction. This effect was dependent on the direct influence of the pineal indole on the heart fibroblasts. The melatonin-induced GAG elevation is blocked by luzindole, the melatonin membrane receptors inhibitor, indicating a direct effect of this indole.

13C-CP-MAS-NMR studies of flavonoids. I. Solid-state conformation of quercetin, quercetin 5'-sulphonic acid and some simple polyphenols

13C-CP-MAS-NMR spectra were measured in order to characterise the orientation of hydroxyl groups of quercetin, quercetin-5'-sulphonic acid and polyphenol-type compounds such as catechol, pyrogallol and gallic acid. The locked conformation of the OH group in the solid results in an increased shielding of carbon proxime to C-OH hydrogen. Carbon shieldings suggest that there is orientational disorder of three OH groups of pyrogallol and gallic acid and that two OH groups of catechol are not equivalent. In solid quercetin and quercetin-5'-sulphonic acid the C7-OH points towards C6-H and the C3'-OH hydrogen is near C2'-H.

Serial transplants of 7,12-dimethylbenz[a]anthracene-induced mammary tumors in Fischer rats as model system for human breast cancer. 3. Quantitative ultrastructural studies of the pinealocytes and plasma melatonin concentrations in rats bearing an advanced passage of the tumor

The aim of the present study was to investigate the ultrastructure of pinealocytes and plasma melatonin concentrations in Fischer rats bearing an advanced (14th) passage 7,12-dimethylbenz[a]anthracene-induced mammary tumor. Quantitative ultrastructural analysis of the cell size and relative volumes of various cell organelles as well as the number of dense-core vesicles was performed in pinealocytes of the animals killed either during the daytime (15.00 h) or at night (3.00 h) 1 month after tumor transplantation. No significant differences between control and tumor-bearing animals were observed either during the daytime or at night. However, plasma melatonin concentrations in tumor-bearing rats killed at 3.00 h were suppressed by 35% (p < 0.025) when compared to the control animals killed at the same time.